Notably, due to the negative correlations observed between SETD4 and various immune cells in some cancer types, BLCA, LUSC, Sarcoma (SARC), SKCM, and UCEC patients with lower SETD4 levels may benefit from immunotherapy. Here, SETD4 is linked to sarcoma.